DTCFF (Defence Therapeutics) Moat Score: 4/10 (As of Jun. 28, 2026)


DTCFF Defence Therapeutics Inc DTCFF
21 GF Score
Price $0.35
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics Moat Score?

Defence Therapeutics DTCFF -2.02% 21 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates DTCFF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,402 Biotechnology companies, Defence Therapeutics ranks better than 88.8% on this metric.

Defence Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Defence Therapeutics has Narrow Moat: Defence Therapeutics has valuable intellectual property in the biotech sector, providing some competitive edge. However, it lacks strong brand strength, customer loyalty, and significant regulatory barriers, resulting in a modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Defence Therapeutics might have Narrow Moat - Discernible but modest moat.

Defence Therapeutics  (OTCPK:DTCFF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Defence Therapeutics Moat Score Related Terms

DTCFF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Defence Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Defence Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Moat Score falls into.


DTCFF
21GF Score
Defence Therapeutics Inc DTCFF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Defence Therapeutics (DTCFF) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Defence Therapeutics ranks #157 out of 1402 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Defence Therapeutics' Moat Score too high?
Defence Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Defence Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Defence Therapeutics ranks #157 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Defence Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Defence Therapeutics ranks #157 out of 1402 companies for Moat Score. This places Defence Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Defence Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Defence Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Defence Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Defence Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Other Exchanges DTC:GermanyDTC:Canada
Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
21GF Score

Get the complete analysis for DTCFF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price